Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

NCT00710528 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Lymphoma, Non-Hodgkin (NHL)
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM)

Interventions

DRUG: CAL-101

Sponsor

Gilead Sciences